CJC / IPA (CJC-1295 5mg + Ipamorelin 5mg Blend)

This formulation combines CJC-1295, a synthetic growth hormone–releasing hormone (GHRH) analogue, with Ipamorelin, a selective growth hormone secretagogue (GHS). Together, these peptides have been investigated in preclinical models for their potential complementary effects on growth hormone pathways.

Key Research Characteristics:

• CJC-1295 – Studied for its ability to bind to and activate GHRH receptors, potentially influencing growth hormone secretion in research models.

• Ipamorelin – Investigated for its selective stimulation of the ghrelin receptor, triggering growth hormone release without significantly affecting cortisol or prolactin in studies.

• Combination approach explored for sustained and synergistic growth hormone pathway activation in laboratory settings.

• High-purity, research-grade formulation.

Intended Use:
For qualified research professionals only. All products are intended for laboratory research purposes and are not approved for human use. Not for human consumption, therapeutic, or diagnostic applications.